Lewin, SR;
Attoye, T;
Bansbach, C;
Doehle, B;
Dubé, K;
Dybul, M;
SenGupta, D;
... Sunnylands 2019 Working Group; + view all
(2021)
Multi-stakeholder consensus on a target product profile for an HIV cure.
The Lancet HIV
, 8
(1)
e42-e50.
10.1016/S2352-3018(20)30234-4.
Preview |
Text
1-s2.0-S2352301820302344-main.pdf - Published Version Download (707kB) | Preview |
Abstract
Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures.
| Type: | Article |
|---|---|
| Title: | Multi-stakeholder consensus on a target product profile for an HIV cure |
| Location: | Netherlands |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S2352-3018(20)30234-4 |
| Publisher version: | https://doi.org/10.1016/S2352-3018(20)30234-4 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10118935 |
Archive Staff Only
 |
View Item |
